Eupraxia Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Eupraxia Pharmaceuticals' valuation are provided below:
Market Capitalization
507.5 M
Earnings Share
(1.20)
We have found one hundred twenty available fundamental signals for Eupraxia Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Eupraxia Pharmaceuticals' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 28th of December 2025, Market Cap is likely to drop to about 89.1 M. In addition to that, Enterprise Value is likely to drop to about 83.4 M
About Eupraxia Pharmaceuticals Financial Statements
Eupraxia Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Eupraxia Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eupraxia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Eupraxia Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eupraxia Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eupraxia Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eupraxia Pharmaceuticals to buy it.
The correlation of Eupraxia Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eupraxia Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eupraxia Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eupraxia Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.